Dexa Scan denied as not FDA-approved for this use by Medicare?

Medicare's specific coverage criteria for dexa scan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Medicare Denies a DEXA Scan as Not FDA-Approved

A "not FDA-approved" denial on a DEXA scan claim is almost certainly a misapplication of denial criteria. DEXA devices used for bone mineral density measurement are FDA-cleared medical devices; the FDA-approval framework for devices differs from drug approval. When this denial appears, it typically means one of the following: (1) the specific device or imaging protocol was flagged erroneously; (2) a research or non-standard application of DEXA was ordered and the claim was coded in a way that triggered an investigational flag; or (3) a Medicare Advantage plan applied an incorrect denial template. In any case, this is a challengeable denial.

## Why This Denial Is Appealable

Standard DEXA bone densitometry is performed on FDA-cleared devices and is covered under Medicare's established Coverage Determinations. Citing "not FDA-approved" as a basis for denying a standard diagnostic DEXA is legally and factually incorrect. The appeal should affirmatively establish that the device used is FDA-cleared and that the clinical application falls within established coverage policy.

## Federal Appeal Framework

• Traditional Medicare: Redetermination within 120 days → QIC Reconsideration within 180 days → ALJ Hearing → Medicare Appeals Council → Federal Court.
• Medicare Advantage: internal appeal (standard or expedited) → ACA §2719 external review by an Independent Review Organization.
• Expedited review is available when delay would seriously jeopardize health.
• Filing Redetermination within 60 days of denial is recommended to preserve the full appeal chain.

## Concrete Appeal Steps

1. Obtain the denial letter and identify the specific language citing non-approval or investigational status. 2. Contact the imaging facility to obtain the device name, manufacturer, and FDA 510(k) clearance or PMA number for the DEXA equipment used. 3. Pull the applicable Medicare NCD or LCD for bone density measurement from cms.gov and confirm the covered indication. 4. Draft an appeal letter that (a) documents FDA clearance of the device, (b) maps the clinical indication to the Coverage Determination, and (c) includes the ordering provider's medical-necessity letter. 5. If the denial involved a non-standard DEXA application, address why that application is consistent with accepted medical practice.

## Documentation Checklist

• Denial notice with the specific rationale cited
• Device FDA clearance documentation (510(k) number or equivalent) from the imaging facility
• Applicable Medicare NCD/LCD printout with covered indications highlighted
• Ordering provider's medical-necessity letter
• Clinical notes supporting the indication for the scan
• Any relevant professional society guidance on the DEXA application ordered

## Criteria-Mapping Structure

Structure the appeal as two parallel arguments: first, the regulatory argument (the device is FDA-cleared — cite the clearance number); second, the clinical-coverage argument (the indication is covered — map each NCD/LCD criterion to the chart fact). Keeping these two tracks clearly separated makes the appeal easier for the reviewer to follow and harder to dismiss.